Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Trial of SB-061 for the Treatment of Symptomatic Osteoarthritis of the Knee

Next Previous
Trial Profile

A Phase 2b Trial of SB-061 for the Treatment of Symptomatic Osteoarthritis of the Knee

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SB 061 (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Nordic Bioscience

Most Recent Events

  • 01 Nov 2024 Results(n=288) evaluating efficacy and safety of intra-articular injections of a novel aggrecan mimetic, SB-061, in subjects with knee osteoarthritis (OA), published in the Osteoarthritis and Cartilage
  • 03 Jun 2023 Primary endpoint (The primary efficacy endpoint is the change from baseline in reported pain as measured by the Western Ontario and McMaster Universities Osteoarthritis Index pain sub-score (WOMAC A 11-point NRS 3.1, 5 questions) in the target knee as evaluated at week 8 of the trial.) has not been met, according to Results presented at the 24th Annual Congress of the European League Against Rheumatism.
  • 03 Jun 2023 Results presented at the 24th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top